Backed by our passionate global community, we are committed to funding and accelerating kidney health research through innovative technologies to translate ground breaking ideas into life-changing solutions.
Apply for research fundingThese are some of the most prevalent issues in kidney health today, that our community aims to solve through funding innovative research.
More than 1 in 7 adults suffer from CDK - an estimated 37 million in the US alone. Globally that number is over 800 million.
Innovative kidney health projects often underfunded, delaying critical treatments from reaching patients.
CKD affects 10% of the global population (800 million people), largely due to inadequate early diagnostic tools.
US annual dialysis costs ranges from $50,000-$120,000; with Medicare spending reaching over $130B.
Significant disparities in kidney care access, particularly affecting low-income and rural areas globally.
Organ shortages lead to illegal kidney trade, a significant issue KidneyDAO aims to address.
KidneyDAO revolutionizes kidney health through innovative funding and global collaboration. We accelerate research, reduce treatment costs, and improve care access, aiming to make effective kidney solutions available worldwide, to those who need it most.
KidneyDAO fast-tracks groundbreaking kidney treatments by leveraging decentralized science and community-driven funding, addressing the slow transition of research to practice and the underfunding of high-risk, high-reward projects.
Through support for advanced early detection technologies and preventive strategies, KidneyDAO works to reduce the global burden of kidney disease, addressing the current limitations in early diagnosis and intervention.
KidneyDAO's focus on accessible innovations and alternative transplant solutions aims to democratize kidney care worldwide, combating inequitable access and addressing the critical issue of kidney trafficking.
By developing cutting-edge AI technologies for monitoring, staffing, and medication management, KidneyDAO tackles the shortage of nephrology professionals, improves early detection, and enhances treatment adherence, ultimately reducing healthcare costs.
KidneyDAO's promotion of transparent, global collaboration in kidney health research accelerates knowledge sharing and innovation, breaking down traditional barriers in the scientific community and speeding up the development of life-saving treatments.
We offer research funding and support for promising and innovative projects in kidney health. Apply funding and learn more about how we can help accelerate your research.
Apply for research funding
The KNEY token enables KidneyDAO's innovative funding process to empowers the community to source, evaluate, and fund promising kidney health projects. Through expert review, community discussion, and transparent on-chain voting, we ensure that promising ideas receive support, accelerating advancements in kidney care worldwide.
KNEY token holders source kidney health projects. KidneyDAO evaluates each project's IP and commercial viability in addressing chronic kidney disease challenges. The Kidney Science Dealflow Working Group, a panel of nephrology experts, reviews promising proposals.
Projects passing initial screening are presented to the KidneyDAO community. Experts provide recommendations, followed by community discussion to ensure alignment with KidneyDAO's mission.
KNEY token holders participate in an on-chain vote for project funding. This decentralized decision-making process ensures transparency and community consensus.
Approved projects receive funding through blockchain-based mechanisms (e.g., IP-NFTs, equity agreements). KidneyDAO supports project development and incubation. Successful outcomes are reinvested in the KidneyDAO treasury and shared with researchers, ensuring sustainable innovation in kidney health.
Everything you need to know about the governance token that powers our community.
The KLF15 Agonist Phase I project targets albuminuria in chronic kidney disease, offering a potentially safer and more effective alternative to glucocorticoid therapy for conditions like FSGS and MCD. With promising efficacy and reduced toxicity, this novel approach is progressing towards patent licensing and IND roadmap development, aiming for accelerated FDA approval.
View project
Smartphone-based Facial remote patient management (RPM) AI, providing an affordable alternative to costly monitoring devices. FDA-cleared and patent-protected, it targets conditions like hypertension and CKD. Ready for deployment, it aims to revolutionize personalized medicine, beginning with mental health.
View project
CareYield leverages blockchain, AI, and community to tokenize healthcare assets, creating a liquid marketplace. It aims to accelerate innovation, improve outcomes, and reduce costs, targeting crypto investors while maintaining regulatory compliance.
View project
KidneyDAO's DeIPA is a revolutionary model that demonstrates the potential of CareYield's platform. By leveraging blockchain technology, artificial intelligence, and tokenization, DeIPA has addressed the limitations of traditional IPAs, unlocking new opportunities for growth, efficiency, and patient care.
View project
The Dialysis AI Humanoid Robotic Staffing project tackles the nephrology professional shortage through an AI-driven staffing platform, patient-provider matching app, and humanoid robots. With a revenue-generating platform already operational and patent-pending AI and robotic solutions in development, it aims to optimize dialysis care delivery and staffing efficiency.
View project
Intel MedPatch AI tackles medication non-compliance through automated lab testing and microneedle drug delivery. This system aims to reduce healthcare costs and medication errors, especially for elderly and rural patients. With patents for CKD and CHF, an obesity management grant, and potential Epogen partnership, it's progressing towards wider application.
View project
Join our active discord community to connect with researchers, patients, and supporters working together to advance the future of kidney health.
